PHASE II STUDY OF THE HISTONE-DEACIETYLASE INHIBITOR ITF2357 IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS

被引：0
|
作者：
Bonfante, V. [1 ]
Viviani, S. [1 ]
Fasola, C. [1 ]
Crippa, F. [1 ]
Marchiano, A. [1 ]
Valagussa, P. [1 ]
Gianni, A. M. [1 ]
机构：
[1] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0605
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [41] A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
    Fehniger, Todd A.
    Larson, Sarah
    Trinkaus, Kathryn
    Siegel, Marilyn J.
    Cashen, Amanda F.
    Blum, Kristie A.
    Fenske, Timothy S.
    Hurd, David D.
    Goy, Andre
    DiPersio, John F.
    Bartlett, Nancy L.
    BLOOD, 2009, 114 (22) : 1422 - 1422
  • [42] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
    Chen, Robert
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie A.
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Zhang, Yinghua
    Ricart, Alejandro D.
    Balakumaran, Arun
    Moskowitz, Craig H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2125 - +
  • [43] A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
    Fehniger, Todd A.
    Watkins, Marcus P.
    Ezenwajiaku, Nkiruka
    Wan, Fei
    Hurd, David D.
    Cashen, Amanda F.
    Blum, Kristie A.
    Goy, Andre
    Fenske, Timothy S.
    Wagner-Johnston, Nina D.
    Carson, Kenneth
    Siegel, Marilyn J.
    Russler-Germain, David
    Schneider, Stephanie E.
    Mehta-Shah, Neha
    Kahl, Brad
    Bartlett, Nancy L.
    HAEMATOLOGICA, 2024, 109 (03) : 953 - 957
  • [44] Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.
    Gui, Lin
    Cheng, Ying
    Wang, Huaqing
    Cao, Junning
    Li, Zhenling
    Zhang, Lei
    Gao, Yuhuan
    Li, Yufu
    Xu, Weijie
    Li, Xiang
    Ke, Xiaoyan
    Jing, Hongmei
    Zhang, Qingyuan
    Xi, Yaming
    Liu, Tingbo
    Wang, Zhen
    Gao, Yajie
    Pan, Qin
    Zou, Liqun
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Stephenson, JJ
    Bartlett, NL
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Hillson, J
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
  • [46] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
    Bartlett, NL
    Gribben, JC
    Boccia, RV
    Milder, MS
    Aboulafia, DM
    Castro, J
    Flinn, I
    Hayes-Lattin, B
    Kaplan, L
    Lin, T
    Lucas, JB
    Maloney, DG
    McLaughlin, P
    McSweeney, PA
    Mohrbacher, A
    Redfern, C
    Steis, R
    Stephenson, JJ
    Strair, R
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [47] Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma
    Gopal, A. K.
    Fanale, M. A.
    Moskowitz, C. H.
    Shustov, A. R.
    Mitra, S.
    Ye, W.
    Younes, A.
    Moskowitz, A. J.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1057 - 1063
  • [48] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Bartlett, NL
    Stephenson, JJ
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Berenson, RJ
    Frohlich, MW
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 76 - 76
  • [49] MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma
    Zappasodi, Roberta
    Cavane, Alessandra
    Iorio, Marilena V.
    Tortoreto, Monica
    Ruggiero, Giusi
    Magni, Michele
    Carlo-Stella, Carmelo
    Tagliabue, Elda
    Zunino, Franco
    Croce, Carlo M.
    Gianni, Alessandro M.
    Di Nicola, Massimo
    BLOOD, 2011, 118 (21) : 1174 - 1174
  • [50] Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
    Strauss, SJ
    Maharaj, L
    Stec, J
    Boral, A
    Trehu, E
    Schenkein, D
    Joel, SP
    Lister, TA
    BLOOD, 2004, 104 (11) : 389A - 389A
12345